British drugmaker GlaxoSmithKline (GSK) is under corruption investigation in China.Anbound research team is in the opinion that this is neither an accident nor an individual case. Through the case, the Chinese government will probably create an opportunity for reform and launch crackdown on drug industry as well as promote the structural reform in the pharmaceutical sector. Anti-corruption drive in the sector may relieve both the pressure in both areas of medical care and finance.